ProCE Banner Series

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

Interact with an expert during a 1-hour, CME/CNE/CPE-certified live meeting examining recent advances and current best practices in treatment for hepatocellular carcinoma and biliary tract cancers. Register today!

  ACPE
  | AMA
  | ANCC
Credits Available

1.0

Who Should Attend

This educational program is intended for hepatologists, medical oncologists, radiation oncologists, surgical oncologists, nurses, pharmacists, and other healthcare professionals who treat patients with hepatocellular carcinoma and biliary tract cancer.

All Events

Past Events

January

26

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

11:30 AM - 1:00 PM Eastern Time (ET)

In-person

Private Event -- Sidney Kimmel Comprehensive Cancer Center

January

31

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

6:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event -- Vidant Health Beaufort Hospital

February

07

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

12:00 PM - 1:00 PM Central Time (CT)

Virtual

February

16

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

7:00 PM - 8:00 PM Eastern Time (ET)

In-person

Private Event -- AAPIQLI / Blood & Cancer Specialists, New York

February

21

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

6:30 PM - 7:30 PM Central Time (CT)

In-person

Private Event -- St. Luke's Hospital, St. Louis, Missouri

February

28

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

3:00 PM - 4:00 PM Mountain Time (MT)

Virtual

Private Event, Rio Rancho, New Mexico

March

06

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

12:00 PM - 1:00 PM Central Time (CT)

Virtual

CCO Simulcast | Host Group AL, Mobile, Alabama

March

09

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data (PRIVATE EVENT)

12:30 PM - 1:30 PM Eastern Time (ET)

Virtual

Private Event, Rockville, Maryland

March

09

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data (PRIVATE EVENT)

6:00 PM - 7:00 PM Central Time (CT)

In-person

Private Event, Madison, Wisconsin

March

16

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

6:30 PM - 7:30 PM Central Time (CT)

Virtual

Private Event, Aurora, Illinois

March

23

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

6:30 PM - 7:30 PM Pacific Time (PT)

Virtual

Private Event, Fresno, California

March

25

2023

Systemic Treatment for Hepatobiliary Cancers in First and Later Lines: Applying the Latest Data

8:15 AM - 9:15 AM Pacific Time (PT)

In-person

Private Event, Las Vegas, Nevada

Topics

  • Introduction and Overview
  • First-line Systemic Therapy for Advanced HCC: Current and Emerging Options
  • Second-line Therapy for Advanced HCC
  • Systemic Therapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
  • BTC: Current and Emerging Immunotherapy and Targeted Therapy Regimens
  • Audience Q&A

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, competence, and performance of learners to integrate current and emerging systemic therapies into the treatment of patients with hepatocellular carcinoma and biliary tract cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor-based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Test tumors for biomarkers that can identify patients with hepatobiliary cancers suitable for targeted therapy
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitors and targeted therapies in patients with HCC or BTC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-196-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

Educational grant(s) provided by

AstraZeneca
Genentech, a member of the Roche Group

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191